Antiprogestins in breast cancer treatment: are we ready?
CLM Lanari, V Wargon, PA Rojas, A Molinolo - 2012 - ri.conicet.gov.ar
Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer
death in females worldwide. It is accepted that breast cancer is not a single disease, but …
death in females worldwide. It is accepted that breast cancer is not a single disease, but …
The unique pharmacological characteristics of mifepristone (RU486): from terminating pregnancy to preventing cancer metastasis
Mifepristone (RU486) is a born‐for‐woman molecule discovered three decades ago. Unlike
those antihypertensive and antipsychotic pharmaceutical blockbusters, this abortifacient …
those antihypertensive and antipsychotic pharmaceutical blockbusters, this abortifacient …
Mifepristone Inhibits Ovarian Cancer Cell Growth In vitro and In vivo
AA Goyeneche, RW Caron, CM Telleria - Clinical Cancer Research, 2007 - AACR
Purpose: These studies were designed to determine whether the synthetic steroid
mifepristone inhibits ovarian cancer growth in vitro and in vivo and the molecular …
mifepristone inhibits ovarian cancer growth in vitro and in vivo and the molecular …
Repositioning of mifepristone as an integrated stress response activator to potentiate cisplatin efficacy in non-small cell lung cancer
J Namkaew, J Zhang, N Yamakawa, Y Hamada… - Cancer Letters, 2024 - Elsevier
Lung cancer, primarily non-small-cell lung cancer (NSCLC), is a significant cause of cancer-
related mortality worldwide. Cisplatin-based chemotherapy is a standard treatment for …
related mortality worldwide. Cisplatin-based chemotherapy is a standard treatment for …
Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor
LN Song, M Coghlan, EP Gelmann - Molecular endocrinology, 2004 - academic.oup.com
Mifepristone is a potent antagonist of steroid hormone receptors such as glucocorticoid and
progesterone receptors. We investigated the potential for mifepristone to act as an …
progesterone receptors. We investigated the potential for mifepristone to act as an …
High progesterone receptor expression in prostate cancer is associated with clinical failure
T Grindstad, S Andersen, S Al-Saad, T Donnem… - PloS one, 2015 - journals.plos.org
Background Prostate cancer is a highly heterogeneous disease and one of the leading
causes of mortality in developed countries. Specific prognostic and predictive markers for …
causes of mortality in developed countries. Specific prognostic and predictive markers for …
DNA damage responses in mammalian oocytes
JK Collins, KT Jones - Reproduction, 2016 - rep.bioscientifica.com
Antiprogestins constitute a group of compounds, developed since the early 1980s, that bind
progesterone receptors with different affinities. The first clinical uses for antiprogestins were …
progesterone receptors with different affinities. The first clinical uses for antiprogestins were …
The prince and the pauper. A tale of anticancer targeted agents
Cancer rates are set to increase at an alarming rate, from 10 million new cases globally in
2000 to 15 million in 2020. Regarding the pharmacological treatment of cancer, we currently …
2000 to 15 million in 2020. Regarding the pharmacological treatment of cancer, we currently …
A phase II study of mifepristone (RU‐486) in castration‐resistant prostate cancer, with a correlative assessment of androgen‐related hormones
OBJECTIVE To evaluate mifepristone (RU‐486) in patients with castration‐resistant prostate
cancer (CRPC), with a correlative assessment of serum androgens and androgen …
cancer (CRPC), with a correlative assessment of serum androgens and androgen …
[HTML][HTML] From Therapy Resistance to targeted therapies in prostate Cancer
Prostate cancer (PCa) is the second most common malignancy among men worldwide.
Although early-stage disease is curable, advanced stage PCa is mostly incurable and …
Although early-stage disease is curable, advanced stage PCa is mostly incurable and …